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Drug price reforms: the new F1–F2 bifurcation
Thomas Faunce, Senior Lecturer, College of Law and Medical School, Australian National 
University, Canberra; and Hans Lofgren, Senior Lecturer, School of International and Political 






the	National Health Amendment (Pharmaceutical Benefits 
Scheme) Act 2007.	At	the	core	of	this	Act	are	new	sections	








































































































































































































Conflict of interest: none declared













Professor Michael Abramson, Associate Professor Christine 








































































































































































Top 10 drugs by cost to Government †
Drug Cost to Government  DDD/1000/day  Prescriptions 
  ($A)  PbS/RPbS ‡ PbS/RPbS ‡  
1.	 atorvastatin	 562	234	406	 131.799	 10	000	495
2.	 simvastatin	 309	227	367	 58.072	 6	231	212
3.	 clopidogrel	 179	983	732	 9.219	 2	404	361
4.	 esomeprazole	 161	102	420	 16.802	 4	428	530
5.	 olanzapine	 157	471	533	 3.073	 775	475
6.	 salmeterol	and	fluticasone	 157	239	113	 –	§	 2	789	814
7.	 omeprazole	 114	030	881	 17.996	 3	882	359
8.	 pravastatin	 		93	389	809	 13.537	 1	870	879
9.	 venlafaxine	 		93	329	210	 11.987	 2	318	531
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Drugs for the doctor's bag
Andrew Baird, General Practitioner, Brighton, Victoria
Summary 
The doctor's bag should contain drugs for medical 
emergencies that may occur in the community. 
Most of these drugs are provided under the 
Pharmaceutical benefits Scheme and can be 
ordered free of charge through a pharmacist. 
General practice accreditation now requires that 
clinics have appropriate emergency drugs as well 
as oxygen and a bag-valve-mask system. Practices 
should also have an up-to-date logbook detailing 
the emergency drug stocks and a system for 
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Table 1
useful drugs for the doctor's bag


























































































































































































































Drug (form) indications Contraindications Cautions




























Prepared by Dr M McCullough of the Australian 
Dental Association
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Evaluation of adrenocortical function in adults
Jui Ho, Endocrinologist, and David J Torpy, Associate Professor, Discipline of Medicine,  




Cushing's syndrome is caused by increased 
concentrations of cortisol. Most cases can be 
detected by measuring the free cortisol in a urine 
sample collected over 24 hours. in Cushing's 
syndrome the increased secretion of cortisol is 
not reduced during a dexamethasone suppression 
test. Addison's disease is caused by a decreased 
secretion of cortisol that does not respond to 
an injection of synthetic adrenocorticotrophic 
hormone. Concentrations of adrenocorticotrophic 
hormone are raised in primary, and low or normal 
in secondary adrenal insufficiency. Some patients 
with hypertension have primary aldosteronism. 
They have a high ratio of aldosterone to plasma 
renin activity. when investigating adrenal function 
it is important to consider the patient's diet and 






































































































Testing for primary hypoadrenalism (Addison's 
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Self-test questions
The following statements are either true or false  





Therapeutic Advice and information Service (TAiS)
A telephone service for health professionals 
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Relationships between health professionals and 
industry: maintaining a delicate balance
Paul A Komesaroff, Professor of Medicine, Director, Centre for the Study of Ethics in 
Medicine and Society, Monash University Department of Medicine, Alfred Hospital, 
Melbourne, and Ethics Convener, Royal Australasian College of Physicians
Summary
The power and influence of the pharmaceutical 
industry has raised concerns among health 
professionals and the wider community and led 
to calls for increased regulation. overwhelming 
evidence that advertising, contact with company 
representatives, gift giving, sponsorship of 
meetings and other forms of promotion influence 
prescribing behaviour, has drawn particular 
attention to drug promotion. in answer to these 
concerns a range of responses has developed, 
including rules set by government, processes for 
the review and management of research, industry 
codes of conduct, community responses, and 
guidelines generated by practitioner associations. 
The various forms of regulation taken together 
strike a delicate balance that aims to protect 
the interests of the community and individual 
patients, foster research and the development 
of new products, maintain public confidence 
in pharmaceuticals and medicine, and facilitate 
ethical decision making among the various 
participants. Although guidelines for health 
professionals provide some advice, they cannot 
cover all situations where conflicts and dualities 
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Dental notes
Prepared by Dr M McCullough of the Australian 
Dental Association
Relationships between health professionals 








































Medicines Australia Code of Conduct: breaches 














The story of one complaint





















































breaches of the Code of Conduct July 2006 – June 2007
Company Drug Sanction imposed by Code of Conduct Committee
brand name generic name







Allergan	Australia Lumigan	 bimatoprost Withdraw	material
Corrective	letter	
$15	000	fine
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Merck	Sharp	&	Dohme Fosamax	Plus	 alendronate	 Withdraw	materials
octapharma	 octanate	 factor	VIII	 Withdraw	materials	
Corrective	letter	
$100	000	fine	reduced	on	appeal	to	$10	000










Sanofi-Aventis	 Stilnox	 zolpidem	 Withdraw	materials	
$5000	fine
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Treatment of myasthenia gravis
Stephen W Reddel, Sydney Neurology, Brain and Mind Research Institute,  
The University of Sydney, and Departments of Neurology and Molecular Medicine, 
Concord Repatriation General Hospital, Sydney
Summary
Myasthenia gravis is a syndrome of weakness 
and fatigue due to dysfunction of the 
neuromuscular junction. it is an antibody-
mediated autoimmune condition with a range 
of moderately effective treatments. occasionally 
patients go into remission spontaneously, but 
most require treatment. Mild disease, such 
as that confined to the ocular muscles, can 
often be treated with pyridostigmine alone. 
More significant or generalised weakness 
requires immunosuppression, principally with 
prednisone and azathioprine. The response 
to immunosuppression is slow, ranging from 
several months to 1–2 years for a full response. 
Short-term use of antibody-based therapy 
such as plasma exchange or intravenous 
immunoglobulin is warranted for more severely 
affected patients. Thymectomy offers the hope of 
drug-free remission but as yet remains unproven. 
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Self-test questions
The following statements are either true or false  















Stephen Reddel is an investigator of the United States National 
Institutes of Health (NIH) randomised clinical thymectomy 
trial currently underway. The NIH has paid for a trial workshop 
including travel. He has also received a consultancy fee from 
Aspreva, marketing company of mycophenolate mofetil for use 
in autoimmune diseases.
Dental notes
Prepared by Dr M McCullough of the Australian 
Dental Association
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AP:	 How did you feel about the diagnosis?
ML:	 Myasthenia	gravis	did	not	mean	anything	to	me,	but	I	was	
glad	that	somebody	now	knew	what	was	wrong	with	me.
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Antipsychotic drugs in pregnancy and 
breastfeeding
Debra Kennedy, Director, MotherSafe, Royal Hospital for Women, and Conjoint Lecturer, 
School of Women’s and Children’s Health, University of New South Wales, Sydney
Summary
There are limited data on the safety of 
antipsychotic drugs in pregnancy and 
breastfeeding. Reports of congenital 
abnormalities in the babies of women taking 
typical antipsychotics are uncommon, although 
chlorpromazine may cause symptoms in 
the neonate. No increased risk with atypical 
antipsychotics has yet emerged. if women 
can be managed with a low dose of a single 
antipsychotic drug the benefits of breastfeeding 
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Telbivudine	offers	a	new	therapy	for	patients	diagnosed	with	
chronic	hepatitis	B	infection.	While	telbivudine	seems	to	
be	effective	at	reducing	viral	loads,	we	do	not	know	if	viral	
resistance	will	become	a	problem.	It	is	not	known	if	this	drug	
will	reduce	the	long-term	complications	associated	with	chronic	
hepatitis	B.
	 manufacturer	declined	to	supply	data	
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